Senzime’s objective is to be market leader in neuromuscular and respiratory-related patient monitoring. This market consists of over 100 million patients each year in operating rooms, post-operative and intensive care units.
Our business model is based on sales of monitors and associated disposable sensors to hospitals and clinics, which generate recurring revenue. Senzime currently has direct sales organizations in the US and Germany and collaborates with distributors on its other main markets. Senzime has also entered into several strategic licensing agreements in product development and sales.
The five cornerstones of our business model to execute our mission of eliminating postoperative complications.
Senzime strives to have strong presence in key markets to drive long-term growth, market segment leadership and attractive stakeholder returns.
Senzime strives to lead the innovation race by long-term investments in science, R&D and clinical affairs – all with a goal to improve patient safety.
Senzime strives to be engaged in smart commercial and industrial partnerships to drive rapid market adoption and connectivity to major monitoring systems.
Senzime strives to support hospitals with know-how to make monitoring standardized, and thereby contributing to eliminated complications and reduced hospital expenses.
Senzime strives to be run with the industry’s most efficient and sustainable operations. All thanks to a passionate team that makes it all happen.
Senzime management is a team of people with extensive global experience in the field of medical devices, healthcare and life science.
Senzime Board of Directors is a global team of experts in business development, clinical research and life science development.